LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 563

Search options

  1. Article ; Online: Optical Intracranial Self-Stimulation (oICSS): A New Behavioral Model for Studying Drug Reward and Aversion in Rodents.

    Song, Rui / Soler-Cedeño, Omar / Xi, Zheng-Xiong

    International journal of molecular sciences

    2024  Volume 25, Issue 6

    Abstract: Brain-stimulation reward, also known as intracranial self-stimulation (ICSS), is a commonly used procedure for studying brain reward function and drug reward. In electrical ICSS (eICSS), an electrode is surgically implanted into the medial forebrain ... ...

    Abstract Brain-stimulation reward, also known as intracranial self-stimulation (ICSS), is a commonly used procedure for studying brain reward function and drug reward. In electrical ICSS (eICSS), an electrode is surgically implanted into the medial forebrain bundle (MFB) in the lateral hypothalamus or the ventral tegmental area (VTA) in the midbrain. Operant lever responding leads to the delivery of electrical pulse stimulation. The alteration in the stimulation frequency-lever response curve is used to evaluate the impact of pharmacological agents on brain reward function. If a test drug induces a leftward or upward shift in the eICSS response curve, it implies a reward-enhancing or abuse-like effect. Conversely, if a drug causes a rightward or downward shift in the functional response curve, it suggests a reward-attenuating or aversive effect. A significant drawback of eICSS is the lack of cellular selectivity in understanding the neural substrates underlying this behavior. Excitingly, recent advancements in optical ICSS (oICSS) have facilitated the development of at least three cell type-specific oICSS models-dopamine-, glutamate-, and GABA-dependent oICSS. In these new models, a comparable stimulation frequency-lever response curve has been established and employed to study the substrate-specific mechanisms underlying brain reward function and a drug's rewarding versus aversive effects. In this review article, we summarize recent progress in this exciting research area. The findings in oICSS have not only increased our understanding of the neural mechanisms underlying drug reward and addiction but have also introduced a novel behavioral model in preclinical medication development for treating substance use disorders.
    MeSH term(s) Animals ; Self Stimulation ; Rodentia ; Reward ; Mesencephalon ; Medial Forebrain Bundle ; Electric Stimulation
    Language English
    Publishing date 2024-03-19
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2019364-6
    ISSN 1422-0067 ; 1422-0067 ; 1661-6596
    ISSN (online) 1422-0067
    ISSN 1422-0067 ; 1661-6596
    DOI 10.3390/ijms25063455
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: β-caryophyllene inhibits heroin self-administration, but does not alter opioid-induced antinociception in rodents.

    Galaj, Ewa / Bi, Guo-Hua / Xi, Zheng-Xiong

    Neuropharmacology

    2024  Volume 252, Page(s) 109947

    Abstract: A growing body of research indicates that β-caryophyllene (BCP), a constituent present in a large number of plants, possesses significant therapeutic properties against CNS disorders, including alcohol and psychostimulant use disorders. However, it is ... ...

    Abstract A growing body of research indicates that β-caryophyllene (BCP), a constituent present in a large number of plants, possesses significant therapeutic properties against CNS disorders, including alcohol and psychostimulant use disorders. However, it is unknown whether BCP has similar therapeutic potential for opioid use disorders. In this study, we found that systemic administration of BCP dose-dependently reduced heroin self-administration in rats under an FR2 schedule of reinforcement and partially blocked heroin-enhanced brain stimulation reward in DAT-cre mice, maintained by optical stimulation of midbrain dopamine neurons at high frequencies. Acute administration of BCP failed to block heroin conditioned place preference (CPP) in male mice, but attenuated heroin-induced CPP in females. Furthermore, repeated dosing with BCP for 5 days facilitated the extinction of CPP in female but not male mice. In the hot plate assay, pretreatment with the same doses of BCP failed to enhance or prolong opioid antinociception. Lastly, in a substitution test, BCP replacement for heroin failed to maintain intravenous BCP self-administration, suggesting that BCP itself has no reinforcing properties. These findings suggest that BCP may have certain therapeutic effects against opioid use disorders with fewer unwanted side-effects by itself.
    Language English
    Publishing date 2024-04-16
    Publishing country England
    Document type Journal Article
    ZDB-ID 218272-5
    ISSN 1873-7064 ; 0028-3908
    ISSN (online) 1873-7064
    ISSN 0028-3908
    DOI 10.1016/j.neuropharm.2024.109947
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Identification of the Risk Genes Associated With Vulnerability to Addiction: Major Findings From Transgenic Animals.

    Jordan, Chloe J / Xi, Zheng-Xiong

    Frontiers in neuroscience

    2022  Volume 15, Page(s) 811192

    Abstract: Understanding risk factors for substance use disorders (SUD) can facilitate medication development for SUD treatment. While a rich literature exists discussing environmental factors that influence SUD, fewer articles have focused on genetic factors that ... ...

    Abstract Understanding risk factors for substance use disorders (SUD) can facilitate medication development for SUD treatment. While a rich literature exists discussing environmental factors that influence SUD, fewer articles have focused on genetic factors that convey vulnerability to drug use. Methods to identify SUD risk genes include Genome-Wide Association Studies (GWAS) and transgenic approaches. GWAS have identified hundreds of gene variants or single nucleotide polymorphisms (SNPs). However, few genes identified by GWAS have been verified by clinical or preclinical studies. In contrast, significant progress has been made in transgenic approaches to identify risk genes for SUD. In this article, we review recent progress in identifying candidate genes contributing to drug use and addiction using transgenic approaches. A central hypothesis is if a particular gene variant (e.g., resulting in reduction or deletion of a protein) is associated with increases in drug self-administration or relapse to drug seeking, this gene variant may be considered a risk factor for drug use and addiction. Accordingly, we identified several candidate genes such as those that encode dopamine D
    Language English
    Publishing date 2022-01-12
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2411902-7
    ISSN 1662-453X ; 1662-4548
    ISSN (online) 1662-453X
    ISSN 1662-4548
    DOI 10.3389/fnins.2021.811192
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Possible Receptor Mechanisms Underlying Cannabidiol Effects on Addictive-like Behaviors in Experimental Animals

    Ewa Galaj / Zheng-Xiong Xi

    International Journal of Molecular Sciences, Vol 22, Iss 134, p

    2021  Volume 134

    Abstract: Substance use disorder (SUD) is a serious public health problem worldwide for which available treatments show limited effectiveness. Since the legalization of cannabis and the approval of cannabidiol (CBD) by the US Food and Drug Administration, ... ...

    Abstract Substance use disorder (SUD) is a serious public health problem worldwide for which available treatments show limited effectiveness. Since the legalization of cannabis and the approval of cannabidiol (CBD) by the US Food and Drug Administration, therapeutic potential of CBD for the treatment of SUDs and other diseases has been widely explored. In this mini-review article, we first review the history and evidence supporting CBD as a potential pharmacotherapeutic. We then focus on recent progress in preclinical research regarding the pharmacological efficacy of CBD and the underlying receptor mechanisms on addictive-like behavior. Growing evidence indicates that CBD has therapeutic potential in reducing drug reward, as assessed in intravenous drug self-administration, conditioned place preference and intracranial brain-stimulation reward paradigms. In addition, CBD is effective in reducing relapse in experimental animals. Both in vivo and in vitro receptor mechanism studies indicate that CBD may act as a negative allosteric modulator of type 1 cannabinoid (CB1) receptor and an agonist of type 2 cannabinoid (CB2), transient receptor potential vanilloid 1 (TRPV1), and serotonin 5-HT 1A receptors. Through these multiple-receptor mechanisms, CBD is believed to modulate brain dopamine in response to drugs of abuse, leading to attenuation of drug-taking and drug-seeking behavior. While these findings suggest that CBD is a promising therapeutic candidate, further investigation is required to verify its safety, pharmacological efficacy and the underlying receptor mechanisms in both experimental animals and humans.
    Keywords cannabidiol ; cocaine ; CB1 receptor ; CB2 receptor ; TRPV1 ; 5-TH ; Biology (General) ; QH301-705.5 ; Chemistry ; QD1-999
    Language English
    Publishing date 2021-12-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  5. Article ; Online: Receptor mechanisms underlying the CNS effects of cannabinoids: CB

    Hempel, Briana / Xi, Zheng-Xiong

    Advances in pharmacology (San Diego, Calif.)

    2021  Volume 93, Page(s) 275–333

    Abstract: Cannabis legalization continues to progress in many US states and other countries. ... ...

    Abstract Cannabis legalization continues to progress in many US states and other countries. Δ
    MeSH term(s) Animals ; Cannabinoid Receptor Agonists/pharmacology ; Cannabinoids/pharmacology ; Cannabinoids/therapeutic use ; Cannabis ; Dronabinol/pharmacology ; Hallucinogens ; Humans ; Receptors, Cannabinoid
    Chemical Substances Cannabinoid Receptor Agonists ; Cannabinoids ; Hallucinogens ; Receptors, Cannabinoid ; Dronabinol (7J8897W37S)
    Language English
    Publishing date 2021-12-13
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Intramural
    ISSN 1557-8925
    ISSN (online) 1557-8925
    DOI 10.1016/bs.apha.2021.10.006
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Mitochondrial Clk1-iron-DAT regulation pathway: a possible new therapeutic target for methamphetamine use disorder.

    Hempel, Briana / Xi, Zheng-Xiong

    Acta pharmacologica Sinica

    2021  Volume 43, Issue 8, Page(s) 1887–1888

    MeSH term(s) Central Nervous System Stimulants ; Dopamine ; Dopamine Plasma Membrane Transport Proteins/physiology ; Iron ; Methamphetamine/pharmacology ; Mitochondria
    Chemical Substances Central Nervous System Stimulants ; Dopamine Plasma Membrane Transport Proteins ; Methamphetamine (44RAL3456C) ; Iron (E1UOL152H7) ; Dopamine (VTD58H1Z2X)
    Language English
    Publishing date 2021-12-06
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1360774-1
    ISSN 1745-7254 ; 0253-9756 ; 1671-4083
    ISSN (online) 1745-7254
    ISSN 0253-9756 ; 1671-4083
    DOI 10.1038/s41401-021-00821-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: Current Perspectives on Selective Dopamine D

    Newman, Amy Hauck / Xi, Zheng-Xiong / Heidbreder, Christian

    Current topics in behavioral neurosciences

    2022  Volume 60, Page(s) 157–201

    Abstract: Over three decades of evidence indicate that dopamine (DA) ... ...

    Abstract Over three decades of evidence indicate that dopamine (DA) D
    MeSH term(s) Humans ; Analgesics, Opioid/therapeutic use ; Dopamine ; Receptors, Dopamine D3/agonists ; Receptors, Dopamine D3/therapeutic use ; Dopamine Antagonists/pharmacology ; Dopamine Antagonists/therapeutic use ; Central Nervous System Stimulants/pharmacology ; Substance-Related Disorders/drug therapy
    Chemical Substances Analgesics, Opioid ; Dopamine (VTD58H1Z2X) ; Receptors, Dopamine D3 ; Dopamine Antagonists ; Central Nervous System Stimulants
    Language English
    Publishing date 2022-05-10
    Publishing country Germany
    Document type Journal Article
    ISSN 1866-3370
    ISSN 1866-3370
    DOI 10.1007/7854_2022_347
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Neutral CB1 Receptor Antagonists as Pharmacotherapies for Substance Use Disorders: Rationale, Evidence, and Challenge.

    Soler-Cedeno, Omar / Xi, Zheng-Xiong

    Cells

    2022  Volume 11, Issue 20

    Abstract: Cannabinoid receptor 1 (CB1R) has been one of the major targets in medication development for treating substance use disorders (SUDs). Early studies indicated that rimonabant, a selective CB1R antagonist with an inverse agonist profile, was highly ... ...

    Abstract Cannabinoid receptor 1 (CB1R) has been one of the major targets in medication development for treating substance use disorders (SUDs). Early studies indicated that rimonabant, a selective CB1R antagonist with an inverse agonist profile, was highly promising as a therapeutic for SUDs. However, its adverse side effects, such as depression and suicidality, led to its withdrawal from clinical trials worldwide in 2008. Consequently, much research interest shifted to developing neutral CB1R antagonists based on the recognition that rimonabant's side effects may be related to its inverse agonist profile. In this article, we first review rimonabant's research background as a potential pharmacotherapy for SUDs. Then, we discuss the possible mechanisms underlying its therapeutic anti-addictive effects
    MeSH term(s) Humans ; Receptor, Cannabinoid, CB1/antagonists & inhibitors ; Rimonabant/therapeutic use ; Substance-Related Disorders/drug therapy ; Cannabinoid Receptor Antagonists/therapeutic use
    Chemical Substances Receptor, Cannabinoid, CB1 ; Rimonabant (RML78EN3XE) ; Cannabinoid Receptor Antagonists
    Language English
    Publishing date 2022-10-17
    Publishing country Switzerland
    Document type Journal Article ; Review ; Research Support, N.I.H., Extramural
    ZDB-ID 2661518-6
    ISSN 2073-4409 ; 2073-4409
    ISSN (online) 2073-4409
    ISSN 2073-4409
    DOI 10.3390/cells11203262
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: The selective D

    Panayi, Marios C / Shetty, Shohan / Porod, Micaela / Bahena, Lisette / Xi, Zheng-Xiong / Newman, Amy Hauck / Schoenbaum, Geoffrey

    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology

    2024  

    Abstract: Chronic psychostimulant use causes long-lasting changes to neural and cognitive function that persist after long periods of abstinence. As cocaine users transition from drug use to abstinence, a parallel transition from hyperactivity to hypoactivity has ... ...

    Abstract Chronic psychostimulant use causes long-lasting changes to neural and cognitive function that persist after long periods of abstinence. As cocaine users transition from drug use to abstinence, a parallel transition from hyperactivity to hypoactivity has been found in orbitofrontal-striatal glucose metabolism and striatal D
    Language English
    Publishing date 2024-04-06
    Publishing country England
    Document type Journal Article
    ZDB-ID 639471-1
    ISSN 1740-634X ; 0893-133X
    ISSN (online) 1740-634X
    ISSN 0893-133X
    DOI 10.1038/s41386-024-01858-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Possible Receptor Mechanisms Underlying Cannabidiol Effects on Addictive-like Behaviors in Experimental Animals.

    Galaj, Ewa / Xi, Zheng-Xiong

    International journal of molecular sciences

    2020  Volume 22, Issue 1

    Abstract: Substance use disorder (SUD) is a serious public health problem worldwide for which available treatments show limited effectiveness. Since the legalization of cannabis and the approval of cannabidiol (CBD) by the US Food and Drug Administration, ... ...

    Abstract Substance use disorder (SUD) is a serious public health problem worldwide for which available treatments show limited effectiveness. Since the legalization of cannabis and the approval of cannabidiol (CBD) by the US Food and Drug Administration, therapeutic potential of CBD for the treatment of SUDs and other diseases has been widely explored. In this mini-review article, we first review the history and evidence supporting CBD as a potential pharmacotherapeutic. We then focus on recent progress in preclinical research regarding the pharmacological efficacy of CBD and the underlying receptor mechanisms on addictive-like behavior. Growing evidence indicates that CBD has therapeutic potential in reducing drug reward, as assessed in intravenous drug self-administration, conditioned place preference and intracranial brain-stimulation reward paradigms. In addition, CBD is effective in reducing relapse in experimental animals. Both in vivo and in vitro receptor mechanism studies indicate that CBD may act as a negative allosteric modulator of type 1 cannabinoid (CB1) receptor and an agonist of type 2 cannabinoid (CB2), transient receptor potential vanilloid 1 (TRPV1), and serotonin 5-HT
    MeSH term(s) Animals ; Behavior, Animal ; Brain/drug effects ; Cannabidiol/pharmacology ; Cannabinoids/pharmacology ; Disease Models, Animal ; Dopamine/metabolism ; Humans ; Methamphetamine ; Piperidines/pharmacology ; Receptor, Cannabinoid, CB1/metabolism ; Receptor, Cannabinoid, CB2/metabolism ; Receptor, Serotonin, 5-HT1A/metabolism ; Recurrence ; Reward ; Self Administration ; Substance-Related Disorders/metabolism ; Substance-Related Disorders/physiopathology ; TRPV Cation Channels/metabolism
    Chemical Substances Cannabinoids ; Piperidines ; Receptor, Cannabinoid, CB1 ; Receptor, Cannabinoid, CB2 ; TRPV Cation Channels ; TRPV1 receptor ; Receptor, Serotonin, 5-HT1A (112692-38-3) ; Cannabidiol (19GBJ60SN5) ; Methamphetamine (44RAL3456C) ; Dopamine (VTD58H1Z2X)
    Language English
    Publishing date 2020-12-24
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2019364-6
    ISSN 1422-0067 ; 1422-0067 ; 1661-6596
    ISSN (online) 1422-0067
    ISSN 1422-0067 ; 1661-6596
    DOI 10.3390/ijms22010134
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top